Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, Horikawa T, Fujimura-Tanaka Y, Hamanoue N, Motonaga R, Tanabe M, Inoue R, Yanase T, Kawanami D. Komatsu S, et al. Among authors: horikawa t. Endocr J. 2020 Jan 28;67(1):99-106. doi: 10.1507/endocrj.EJ19-0428. Epub 2019 Nov 27. Endocr J. 2020. PMID: 31776304 Free article.
Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T, Nomiyama T, Kawanami T, Hamaguchi Y, Horikawa T, Tanaka T, Irie S, Motonaga R, Hamanoue N, Tanabe M, Nabeshima K, Tanaka M, Yanase T, Kawanami D. Shigeoka T, et al. Among authors: horikawa t. J Diabetes Investig. 2020 Sep;11(5):1137-1149. doi: 10.1111/jdi.13247. Epub 2020 Apr 9. J Diabetes Investig. 2020. PMID: 32146725 Free PMC article.
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, Fukuda T, Motonaga R, Tanabe M, Yanase T; Collaborators of Fukuoka Study of Ipragliflozin (FUSION) trial. Nomiyama T, et al. Among authors: horikawa t. Endocr J. 2018 Aug 27;65(8):859-867. doi: 10.1507/endocrj.EJ18-0022. Epub 2018 May 26. Endocr J. 2018. PMID: 29806620 Free article. Clinical Trial.
Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
Terawaki Y, Iwaya C, Nomiyama T, Shimono D, Horikawa T, Fujimura-Tanaka Y, Shigeoka T, Hamanoue N, Motonaga R, Tanabe M, Yanase T, Kawanami D; Collaborators in the Repaglinide Glucose Oscillation Study in Fukuoka (REGO-F) trial. Terawaki Y, et al. Among authors: horikawa t. Diabetol Int. 2020 Feb 14;11(3):274-282. doi: 10.1007/s13340-020-00426-w. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802709 Free PMC article.
50-Gb/s ring-resonator-based silicon modulator.
Baba T, Akiyama S, Imai M, Hirayama N, Takahashi H, Noguchi Y, Horikawa T, Usuki T. Baba T, et al. Among authors: horikawa t. Opt Express. 2013 May 20;21(10):11869-76. doi: 10.1364/OE.21.011869. Opt Express. 2013. PMID: 23736409 Free article.
344 results